What is Theravance Biopharma's market cap?

Theravance Biopharma (TBPH) has a market capitalization of $873.8M and trades on NASDAQ.

What is Theravance Biopharma's revenue and profitability?

Theravance Biopharma generated $109.8M in trailing twelve-month revenue with net income of $114.5M, representing a net margin of 104.3%. Gross margin stands at 60.8%. These figures are based on the Q1 2026 filing.

Who are Theravance Biopharma's competitors?

Theravance Biopharma's key competitors include Liquidia Corporation Common Stock, Gyre Therapeutics, Inc. Common Stock, Royalty Pharma plc Class A Ordinary Shares, and others. These companies compete in similar markets and product categories.

Who does Theravance Biopharma partner with?

Theravance Biopharma's notable partners include Viatris Inc., GSK plc, Royalty Pharma Investments, and others.

What subsidiaries does Theravance Biopharma have?

Theravance Biopharma's subsidiaries include Theravance Respiratory Company, LLC.

Where is Theravance Biopharma headquartered?

Theravance Biopharma is headquartered in Cayman Islands and employs approximately 99 people. It has been publicly traded since 2014.

Theravance Biopharma

TBPH

Theravance Biopharma is a biopharmaceutical company focused on the development and commercialization of respiratory and specialty medicines.

Market cap

$873.82M+57.9%

Revenue$109.8M+68.2%

Net income$114.5M+296%

EPS (diluted)$2.20+286%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$17.7MMiss by $84.3K EPS-$0.10Miss by $0.12

Read the full report

Next report

Aug 11, 2026 (In 1 week)

Revenue estimate$22.5M

EPS estimate$0.07

Financials

Q1 2026

Income statement

See full

Revenue$17.7M+15.0%

Operating income-$9.5M+34.3%

Net income-$4.9M+63.7%

EPS (diluted)-$0.10+63.0%

Balance sheet

See full

Cash & equivalents$288.1M+160%

Total debt$40.5M-15.9%

Total equity$290.6M+75.1%

Total assets$472.3M+37.5%

Cash flow

See full

Operating cash flow$73.3M+70.3%

Valuation & ratios

Valuation

See full

Market cap$873.82M+57.9%

Enterprise value$626.23M+97.2%

P/E7.6×-34.8×

P/S8×+0.8×

Profitability

See full

Operating margin1.2%+0.6pp

Net margin104.3%+71.4pp

Returns & leverage

See full

Return on equity50.2%+36.2pp

Debt / equity0.1×-0.2×

Current ratio13.1×+8.4×

Segments

By segment

See full

Single Reportable$17.7M+15.0%

Competitors

By market cap

United Therapeutics$26.3B+95.5%

Royalty Pharma$26.0B+66.7%

LQD

Liquidia Corporation$7.5B+343%

Theravance Biopharma$873.8M+58.0%

Rigel Pharmaceuticals$691.8M+93.6%

Gyre Therapeutics, Inc.$683.4M-3.5%

Zevra Therapeutics, Inc.$574.0M-2.9%

Puma Biotechnology$406.7M+145%

By revenue growth

LQD

Liquidia Corporation+1,937%

Zevra Therapeutics, Inc.+201%

Theravance Biopharma+68.2%

Rigel Pharmaceuticals+47.6%

Gyre Therapeutics, Inc.+16.3%

Royalty Pharma+7.8%

United Therapeutics+5.9%

By net margin

Rigel Pharmaceuticals121.51%+103pp

Theravance Biopharma104.34%+194pp

Zevra Therapeutics, Inc.101.58%+328pp

United Therapeutics40.61%+0.2pp

Royalty Pharma33.9%-14.4pp

Gyre Therapeutics, Inc.6.29%-13.8pp

LQD

Liquidia Corporation-176.24%+896pp

Profile

Theravance Biopharma is a biopharmaceutical company focused on the development and commercialization of respiratory and specialty medicines. The company leverages its organ-selective drug discovery expertise to deliver therapies for chronic obstructive pulmonary disease (COPD) and other conditions. Its primary value proposition is centered on maximizing the commercial potential of its FDA-approved respiratory treatments and optimizing shareholder value through strategic royalty interests.

Competitive position

Theravance Biopharma is a specialized player in the respiratory market, maintaining a significant commercial partnership for its lead nebulized COPD treatment while transitioning toward a leaner, commercial-focused organizational structure.

GeographiesUnited States, China, European Union

Customer segmentsHealthcare providers, Pharmaceutical partners

Business modelProduct sales, Licensing and Royalties, Profit sharing

SuppliersContract manufacturing organizations, API suppliers, Clinical research organizations

CustomersWholesalers, Pharmacies, Hospitals, Healthcare professionals

CountryCayman Islands

Listed2014

Employees99.0

CEORick E. Winningham

SectorHealthcare

IndustryBiotechnology

Websitetheravance.com

FilingsSEC EDGAR

Ask your AI about Theravance Biopharma.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Theravance Biopharma's market cap?: Theravance Biopharma (TBPH) has a market capitalization of $873.8M and trades on NASDAQ.
What is Theravance Biopharma's revenue and profitability?: Theravance Biopharma generated $109.8M in trailing twelve-month revenue with net income of $114.5M, representing a net margin of 104.3%. Gross margin stands at 60.8%. These figures are based on the Q1 2026 filing.
Who are Theravance Biopharma's competitors?: Theravance Biopharma's key competitors include Liquidia Corporation Common Stock, Gyre Therapeutics, Inc. Common Stock, Royalty Pharma plc Class A Ordinary Shares, and others. These companies compete in similar markets and product categories.
Who does Theravance Biopharma partner with?: Theravance Biopharma's notable partners include Viatris Inc., GSK plc, Royalty Pharma Investments, and others.
What subsidiaries does Theravance Biopharma have?: Theravance Biopharma's subsidiaries include Theravance Respiratory Company, LLC.
Where is Theravance Biopharma headquartered?: Theravance Biopharma is headquartered in Cayman Islands and employs approximately 99 people. It has been publicly traded since 2014.